imphatec develops long-term implantable drug delivery devices for chronic disease and women’s health treatment management.
IMPHATEC has raised $2.0M in total funding. The most recent round was Seed. The last funding was announced in October 2026.
IMPHATEC's investors include SynBioVen.
IMPHATEC is headquartered in London, United Kingdom.
imphatec develops long-term implantable drug delivery devices for chronic disease and women’s health treatment management.
IMPHATEC is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IMPHATEC — Funding & Investors." VCBacked, October 19, 2026, https://www.vcbacked.co/company/imphatec. Accessed November 1, 2026.
VCBacked. (2026). IMPHATEC — Funding & Investors. Retrieved November 1, 2026, from https://www.vcbacked.co/company/imphatec
{{cite web |title=IMPHATEC — Funding & Investors |url=https://www.vcbacked.co/company/imphatec |website=VCBacked |access-date=November 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated